Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J. Nastoupil, Frederick L. Locke, Javier Muñoz et al.|Journal of Clinical Oncology|2020Cited by 782
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Michael Dickinson et al.|Nature Medicine|2021Cited by 523
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisMahasweta Gooptu, Mary Eapen, Rizwan Romee et al.|Blood|2021Cited by 163
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remissionArmin Rashidi, Richard F. Olsson, Mehdi Hamadani et al.|Blood Advances|2019Cited by 128
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Doris K. Hansen, Surbhi Sidana et al.|Journal of Hematology & Oncology|2024Cited by 46